Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05080842 · ClinicalTrials.gov registry record · Phase 1
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
A Phase 1 study, sponsored by Accutar Biotechnology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05080842: Clinical Trial Phase 1 study, sponsored by Accutar Biotechnology.
NCT05080842 is a Phase 1 study that was terminated before completion, run by Accutar Biotechnology. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05080842, a Phase 1 study, was terminated before completion, sponsored by Accutar Biotechnology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC682 that can be given safely to participants * To evaluate the side effects of AC682 * To evaluate pharmacokinetics of AC682 * To evaluate the effectiveness of AC682
Interventions
- DRUG AC682
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-11-12 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 1 |
Why NCT05080842 stopped before completion
NCT05080842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which AC682 is the first listed.
NCT05080842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05080842 about?
NCT05080842 is a clinical study titled "A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer". This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC682 that can be given sa...
What is the current status of trial NCT05080842?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-11-12. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT05080842?
The interventions under investigation include: AC682 (DRUG).
Who is sponsoring clinical trial NCT05080842?
This trial is sponsored by Accutar Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05080842's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI